Shared Care Agreements for Medicines
|
|
- Warren Cameron
- 5 years ago
- Views:
Transcription
1 Shared Care Agreements for Medicines Author: Scott Garden, Chief Pharmacist, Acute Services Version: 1.0 Authorised by: NHS Fife Area Drug and Therapeutics Committee Date of Authorisation: Review Date: February 2018 Date added to ADTC website Key Words: policy; procedures; shared care; medicines; shared care agreement Comments: Only relevant on day of printing. Page 1 of 13
2 Policy and Procedures for the Shared Care of Medicines 1.0 Introduction Aim of the Policy Policy Objectives Scope Philosophy, Principles and Objectives Roles and Responsibilities Patients Relatives and Carers NHS Fife Staff References Appendices 7 Appendix 1: 8 Process for agreeing shared care for individual patient Appendix 2: 9 Process for development and approval of SCA Appendix 3: 10 Template for SCA
3 Policy and Procedures for the Shared Care of Medicines 1.0 Introduction Shared care arrangements aim to facilitate the seamless transfer of individual patient care from secondary care to general practice. They are intended for use when medicines, often prescribed for potentially serious conditions and complex by their very nature, are initiated in secondary care and then prescribed by a prescriber in primary care. These medicines will often have a relatively high adverse effect profile and may require specific monitoring. 1 Clearly defined processes and good communication are essential components to shared care. Prescribers must be aware of their responsibilities when prescribing and primary care prescribers must receive comprehensive information to allow safe and effective prescribing. 1 Clear communication, effective collaboration between patients and healthcare professionals and smooth continuity of care are key elements of the NHS Fife Clinical Strategy and the Healthcare Quality Strategy for NHSScotland. 2 NHS Circular No 1992 (GEN) 11 Responsibility for Prescribing between Hospitals and GPs states that a consultant should seek the agreement of the GP to share care of a patient. Information regarding dosage, administration and monitoring should be provided by the consultant for the GP. 3 Decisions about who should take responsibility for continuing care or treatment after initial diagnosis or assessment should be based on the patient s best interests, rather than on convenience or cost of the medicine and associated monitoring or follow-up. 4 Shared care arrangement eligibility criteria For the purposes of this policy a medicine is considered to be eligible for a shared care arrangement if it can be initiated in secondary care and then prescribed by a GP in primary care 1 and meets the following criteria: prescribed for a potentially serious condition 1 complex 1 [intended use likely to be out with the clinical experience of the primary care prescriber] relatively serious effect profile 1 may require specific monitoring and dose titration 1 new, or rarely prescribed 4 Shared care terminology A new term will be used to describe the document which sets out the shared care arrangements, and this is the shared care agreement (SCA). This term is in line with current terminology. These documents have been known in NHS Fife as shared care protocols (SCPs). 1.1 Aim of the Policy The aim of the policy is to ensure safe and effective prescribing and monitoring of medicines across secondary and primary care. 1.2 Policy Objectives This policy will define circumstances under which medicines will be considered appropriate for shared care and will support prescribing and monitoring across the secondary/primary care
4 interface. 1.3 Scope This policy is applicable to patients being treated within primary care and secondary care across NHS Fife. Existing shared care protocols will be reviewed against the new criteria as set out in this policy. The process for agreeing shared care for individual patients is outlined in Appendix 1. The process for development and approval of SCAs is outlined in Appendix 2. The template for SCAs is included as Appendix 3. A medicine intended for shared care use may be used under its licence or may also be off licence. The Policy for the use of Unlicensed medicines and Off-label use of medicines in NHS Fife 5 provides guidance on the use of unlicensed and off label medicines intended for long term use. 2.0 Philosophy, Principles and Objectives This policy seeks to ensure patients have equitable access to medicines across secondary and primary care and that information is communicated effectively. This is in line with recommendations in a Joint Report from the National Pharmaceutical Forum and the Scottish Medical and Scientific Advisory Committee, and the Healthcare Quality Strategy for NHSScotland 2, which includes as priorities: and states: Clear communication and explanation about conditions and treatment Effective collaboration between clinicians, patients and others Continuity of care Mutually beneficial partnerships between patients, their families and those delivering healthcare services which respect individual needs and values and which demonstrate compassion, continuity, clear communication and shared decision-making. 3.0 Roles and Responsibilities 3.1 Patients To inform the specialist team, prescriber or other healthcare professional if he or she does not have a clear understanding of the treatment. To report any adverse effects to the specialist team, prescriber or other healthcare professional involved in their care. To share any concerns about their treatment and compliance with the specialist team, prescriber or other healthcare professional involved in their care. To be available for monitoring and follow up appointments as required. 3.2 Relatives and Carers To support the patient in fulfilling their roles and responsibilities as outlined above.
5 3.3 NHS Fife Staff Clinicians Consultant Be aware of the existence of SCAs and their role within the organisation. Identify complex treatments routinely used in the specialist setting that require an SCA to facilitate accessibility and safe prescribing in primary care. Initiate the process of developing a SCA for the identified treatments, in the agreed format (Appendix 3). Remember to involve relevant people in the development of the SCA from primary care, in particular GPs. Chair of the GP Clinical Steering Group will identify a GP to be involved in the development process. Be responsible for the ongoing review of the SCA. Assume clinical responsibility for the guidance given in the SCA. Evaluate the suitability of the patient for treatment. Advise patient of unlicensed status of treatment if appropriate, and what this may mean for their treatment in line with NHS Fife policy. Undertake baseline monitoring and assessment. Initiate treatment and any associated training and counselling required. Provide an initial supply of treatment until patient s condition is stable. Communicate with the prescriber in primary care to obtain agreement to share the patient s care and provide relevant information and advice. Initial monitoring of treatment until the patient s condition is stable; the patient is demonstrably benefiting from the treatment and is free from any significant side effects. Follow up and monitor the patient at appropriate intervals. If the GP or prescriber in primary care feels unable to accept clinical responsibility for prescribing then the consultant must continue to prescribe the treatment to ensure accessibility. Define the criteria for removal / discontinuation of the medicine. Identify and communicate any relevant polypharmacy issues Provide clear and effective communication with patient, relatives and carers, and use of communication support if necessary General Practitioner/Primary Care Prescriber Be aware of the existence of SCAs and their role within the organisation. Contribute to the development of SCAs in partnership with secondary care colleagues. Ensure that they have sufficient clinical knowledge about the treatment and are
6 prepared to take clinical responsibility for prescribing. Liaise with consultant to agree to share the patient s care in line with the SCA.
7 Policy and Procedures for the Shared Care of Medicines Prescribe the medication as outlined in the SCA. Follow specialist advice on any changes in treatment as indicated in the SCA. Refer back to the specialist in the event of deteriorating clinical condition or any aspect of patient care that is of concern to the GP/Primary Care Prescriber and may affect treatment. Undertake appropriate monitoring and any other responsibilities listed in the SCA. Provide clear and effective communication with patient, relatives and carers, and use of communication support if necessary Clinical Directors, Associate Medical Director, Directorate Management Teams, Health and Social Care Partnership Managers and Clinical Directors Ensure medicines use is in line with NHS Fife medicines governance policies. Consider the resource implications of implementation of SCAs in primary care Medicines Governance Committees Facilitate the development of SCAs, to ensure a smooth transition of care of patients from secondary care to primary care and vice versa, with reference to this policy and procedures. The NHS Fife Area Drug and Therapeutics Committee (ADTC) will advise on the appropriate place in therapy of new drugs following national recommendations (SMC/HIS/SIGN/NICE). Submissions for inclusion of a new medicine in the NHS Fife Joint Formulary should include consideration for the suitability of shared care prescribing. A medicine intended for shared care use may be used under its licence or may also be off-licence. The Managed Service Drug and Therapeutics Committee (DTC) and the GP Clinical Steering Group will work together to support an efficient process of review, approval and implementation. SCAs can be submitted simultaneously to these committees, depending on meeting schedules. The Managed Service DTC is responsible for confirming that secondary care aspects of an SCA will be acceptable. The GP Clinical Steering Group is responsible for confirming that primary care aspects of a SCA will be acceptable. The Area Drug and Therapeutics Committee is responsible for the approval of SCAs Hospital Clinical Pharmacist Contribute to the development of SCAs in collaboration with the prescribing clinicians and to co-ordinate the revision of existing shared care protocols/agreements that are approaching their review date in association with the specialist team Primary Care Pharmacist Support GPs/Primary Care Prescribers with the provision of advice on the use of SCAs.
8 Policy and Procedures for the Shared Care of Medicines 4.0 References 1. National Prescribing Centre. Shared Care of Medicines. Five Minute guide series The Healthcare Quality Strategy for NHS SCOTLAND. The Scottish Government, May NHS Circular 1992 (GEN) 11 Responsibility for Prescribing Between Hospitals and GPs. The Scottish Office. 4. Good practice in prescribing and managing medicines and devices. General Medical Council. Came into effect 25 February Policy for the use of Unlicensed Medicines and the Off label medicines in NHS Fife. Code of Practice for Medicines Version 1 29 October Policy for the use of Unlicensed Medicines and the "Off-label" use of Medicines - Policies 6. Patients and their medicines in hospital. Joint Report, National Pharmaceutical Forum and Scottish Medical and Scientific Advisory Committee. NHS Circular: HDL (2006) 14. Scottish Executive Health Department. February Appendices Appendix 1: Process for agreeing shared care for individual patient Appendix 2: Process for development and approval of SCA Appendix 3: Template for SCA
9 Policy and Procedures for the Shared Care of Medicines Appendix 1 Process for agreeing shared care for individual patient Clinically stable patient requires complex treatment and consultant wishes to propose sharing of care with GP GP agrees to share the patient s care in line with SCA GP is unable to accept clinical responsibility and declines to prescribe Consultant provides relevant Information and advice to GP Consultant continues to prescribe GP prescribes in line with SCA
10 Appendix 2 Process for development and approval of SCA Medicine is approved in Fife and meets the eligibility criteria for shared Care as set out in this policy Clinical team drafts SCA in agreed format (appendix 3) with involvement of relevant people from both secondary and primary care, in particular GPs. Chair of GP Cluster Quality Leads Group to identify GP to support development process Managed Service DTC confirms that acute care aspects of the SCA will be acceptable GP Clinical Steering Group confirms that Primary Care aspects of the SCA will be acceptable Approved by ADTC YES: SCA added to NHS Fife ADTC Website NO: Revised if appropriate and resubmitted
11 Policy and Procedures for the Shared Care of Medicines Appendix 3 Template for SCA SHARED CARE AGREEMENT Name of Medicine: Indication: Version: Approval Date: DD MM YYYY Review Date: DD MM YYY The Shared Care Agreement (SCA) is intended to facilitate the accessibity and safe prescribing of complex treatments across the secondary/primary care interface.it does not contain all of the relevant product information, which should be sought using the current Brisitsh National Formulary and Manufacturer s Summary of Product Characteristics. The SCA must be used inconjuction with the NHS Fife Policy and Procedures for the Shared Care of Medicines, available at:- Roles and Responsibilities List below specific responsibilities that are additional to those detailed in the policy Listed below are specific responsibilities that are additional to those included in the NHS Fife Policy and Procedures for Shared Care. Please refer to the policy for core roles and responsibilities that apply to all Shared Care Agreements. Consultant:- Please give specific information where this will be helpful to the primary care prescriber e.g. Initiation of therapy with drug X over a one month period, then supply of the medicine for one further month once the patients treatment is stable Patient Monitoring 3 monthly for the first 12 months, then 6 monthly in the longer term Reference to criteria for removal / discontinuation of medicine Identification of any specific polypharmacy issues related to the medicine General Practitioner/Primary Care Prescriber Patients, Relatives, Carers If there are no specific responsibilities that are additional to those included in the NHS Fife Policy and Procedure for Shared Care, please include the statement As listed in the NHS Fife Policy and Procedures for the Shared Care of Medicines. Support and Advice for the GP/Primary Care Prescriber e.g. Contact points, telephone numbers, supportive
12 Key Information on the medicine Please refer to the current edition of the British National Formulary (BNF), available at and Summary of the Product Characteristics (SPC), available at for detailed product and prescribing information and specific guidance. Background to disease and use of drug for the given indication Brief paragraph Indication Specific to approved use in NHS Fife (check formulary status) Dosage and Administration Include only where no SPC is available i.e. for unlicensed/ off-label use, and in-line with approved use in NHS Fife Monitoring Page 11 of 13 Test Frequency Abnormal Result Action if Abnormal Result Approved for use by the Managed Service Drug and Therapeutics Committee- relevant date and the GP Clinical Steering Group - relevant date
13 Policy and Procedures for the Shared Care of Medicines Appendix 4 Template for the removal of an NHS Fife Shared Care Protocol Application to request removal of an NHS Fife Shared Care Protocol (SCP) Clinical teams have been invited to review existing SCPs in line with the NHS Fife Policy and Procedures for the Shared Care of Medicines and in line with the eligibility criteria for SCAs, and to consider whether the current SCPs are to be withdrawn or replaced with an SCA, as appropriate in line with the eligibility criteria. All new shared care documentation will be prepared using the new shared care agreement (SCA) template, available as a Word template along with the policy on the NHS Fife ADTC website add link Shared care arrangement eligibility criteria For the purposes of this policy a medicine is considered to be eligible for a shared care arrangement if it can be initiated in secondary care and then prescribed by a GP in primary care 1 and meets the following criteria: prescribed for a potentially serious condition 1 complex 1 [intended use likely to be out with the clinical experience of a GP] relatively high adverse effect profile 1 may require specific monitoring and dose titration 1 new, or rarely prescribed 3 Title of SCP Revision Date Current usage in secondary care (most recent 12 months data) Current usage in primary care (most recent 12 months data) Number of items: Total cost: Number of items: Total cost: Responsible pharmacist Summary of reasons that SCP is no longer required Does the drug continue to be used for the indication given in the SCP? Are alternative drugs now used for this indication? If yes, give details Is the drug currently used for other indications? Has the SMC provided any specific recommendations and restrictions on the prescribing of this drug?
14 Policy and Procedures for the Shared Care of Medicines Template completed by Date Date presented at GP Clinical Steering Group Comments from GP Clinical Steering Group Agreement that SCP be removed Yes / No References 1. National Prescribing Centre. Shared Care of Medicines. Five Minute Guide Series The Healthcare Quality Strategy for NHSScotland. The Scottish Government, May Good practice in prescribing and managing medicines and devices. General Medical Council. Came into effect 25 February
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More informationNHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)
SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) CONTENTS POLICY SUMMARY... 2 1. SCOPE... 4 2. AIM... 4 3. BACKGROUND... 4 4. POLICY STATEMENTS... 5 4.1. GENERAL STATEMENTS... 5 4.2 UNLICENSED
More informationabcdefghijklmnopqrstu
Directorate for Chief Medical Officer, Public Health and Sport Sir Harry Burns, MPH FRCS (Glas) FRCP(Ed) FFPH Health and Social Care Directorate Pharmacy and Medicines Division Professor Bill Scott, MSc,
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationPrinciples of Shared Care Protocols
Principles of Shared Care Protocols 1 Robust shared care arrangements facilitate the safe transition of medicines for use in a specified condition between secondary and primary care clinicians with the
More informationApologies for absence were noted from Ms Claire Dobson, Dr I Gourley, Dr J Kennedy, Professor S McLean, Mr I Mohammed.
CONFIRMED MINUTES OF THE MEETING OF THE FIFE DRUGS AND THERAPEUTICS COMMITTEE HELD AT 12.30PM ON WEDNESDAY 4 OCTOBER 2017 IN MEETING ROOM 2, WARD 6, VICTORIA HOSPITAL, KIRKCALDY. Present: Dr Frances Elliot
More informationabcdefghijklmnopqrstu
Healthcare Policy and Strategy Directorate Quality Division Dear Colleague INTRODUCTION AND AVAILABILITY OF NEWLY LICENSED MEDICINES IN THE NHS IN SCOTLAND Dear Colleague This guidance sets out the policy
More informationUnlicensed Medicines Policy
Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention
More informationPGDs are permitted for use only by registered health professionals (see enclosed link for full list
NHS England North - Yorkshire and the Humber Region Protocol for the Development, Authorisation and Use of Patient Group Directions for the National Immunisation Programmes 1. Introduction The preferred
More informationUncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES
Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company
More informationProcess and methods Published: 23 January 2017 nice.org.uk/process/pmg31
Evidence summaries: process guide Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPRESCRIBING SUPPORT TECHNICIAN:
PRESCRIBING SUPPORT TEAM AUDIT: CARDURA XL (Updated Sept 09) DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Cardura XL is a once daily, extended release preparation of doxazosin
More informationBest Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP
Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse
More informationGuidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products
Title: Identifier: Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products NHSG/guid/PharmInd/GMMG/738 Replaces:
More information5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM (PACS) TIER 2
NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 5: NON-FORMULARY PROCESSES 5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM
More informationSouth East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide
South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide 1. Introduction 1.1 This policy has been developed by the South East London Clinical Commissioning
More informationBEST PRACTICE GUIDANCE-SUPPLEMENTARY PRESCRIBING
BEST PRACTICE GUIDANCE-SUPPLEMENTARY PRESCRIBING NON MEDICAL PRESCRIBING ADVISOR IMPLEMENTATION DATE: MAY 2009 REVIEW DATE: MAY 2010 Supplementary Prescribing The working definition of supplementary prescribing
More informationSUPPLEMENTARY PRESCRIBING: PHARMACIST PRACTITIONERS
SUPPLEMENTARY PRESCRIBING: PHARMACIST PRACTITIONERS A Guide for Implementation within NHSScotland Scottish Executive Health Department SUPPLEMENTARY PRESCRIBING: PHARMACIST PRACTITIONERS A Guide for Implementation
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for
More informationPolicy and procedures for the use of unlicensed medicines
Policy and procedures for the use of unlicensed medicines Unique ID: NHSL. Author (s): Unlicensed Medicines Short-Life Working Group Category/Level/Type: Version: 3.0 Status: DRAFT Authorised by: Area
More informationPrimary - Secondary Care Interface Management
Primary - Secondary Care Interface Management The Scottish Example Ken Paterson PPRI Conference - Vienna 29 September 2011 NHS Scotland Virtually monopoly payer and provider Universal coverage from general
More informationScottish Medicines Consortium. A Guide for Patient Group Partners
Scottish Medicines Consortium Advising on new medicines for Scotland www.scottishmedicines.org page 1 Acknowledgements Some of the information in this booklet is adapted from guidance produced by the HTAi
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% FOR THE TREATMENT OF IMPETIGO BY COMMUNITY PHARMACISTS UNDER THE PHARMACY FIRST SERVICE IN NHS HIGHLAND THE COMMUNITY PHARMACIST SEEKING
More informationTitle: Replacement of the Commissioning Advisory Forum Agenda Item: 9
Meeting of Bristol Clinical Commissioning Group To be held on Tuesday, 2 July 2013 commencing at 1.30 pm in the BAWA Centre Title: Replacement of the Commissioning Advisory Forum Agenda Item: 9 1 Purpose
More informationPHARMACEUTICAL REPRESENTATIVE POLICY NOVEMBER This policy supersedes all previous policies for Medical Representatives
PHARMACEUTICAL REPRESENTATIVE POLICY VEMBER 2017 This policy supersedes all previous policies for Medical Representatives Policy title Pharmaceutical Representative Policy Policy PHA39 reference Policy
More informationNon Medical Prescribing Policy
Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:
More informationMedicines Reconciliation: Standard Operating Procedure
Clinical Medicines Reconciliation: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationBest Practice Statement ~ March Patient Group Directions
Best Practice Statement ~ March 2006 Patient Group Directions NHS Quality Improvement Scotland 2005 ISBN 1-84404-403-3 First published March 2006 NHS Quality Improvement Scotland (NHS QIS) consents to
More informationNHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF
NHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF This guidance relates to all staff employed by NHS Fife (including staff within the Health &
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Unlicensed Medicines Policy Version.: 2.4 Effective From: 13 October 2016 Expiry Date: 13 October 2018 Date Ratified: 12 October 2016 Ratified By:
More informationPrescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services
Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Document Purpose Version 2.2 To detail the specific contractual issues associated with prescribing
More informationGG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationNPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing
NPSA Alert 03: Reducing the harm caused by oral Methotrexate Implementation Progress Report July 2006 Learning and Sharing CONTENTS Page 1 Background 3 2 Findings 4 Appendix 1 Summary of responses 6 Appendix
More informationTemplate (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment
Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment The PRN Purpose & Outcome Protocol (PRN POP) Background The term PRN (from
More informationPCA (P) (2016) 1. Background
Healthcare Quality and Strategy Directorate Pharmacy and Medicines Division Dear Colleague STOMA APPLIANCE SERVICE IN THE COMMUNITY PUBLICATION OF STOMA CARE QUALITY AND COST EFFECTIVENESS REVIEW REPORT
More informationMEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY
MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY NHS employees and contractors link with the pharmaceutical industry in a number of ways, as a source of information, through the receipt
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More informationNHS PCA (P) (2015) 17. Dear Colleague
Healthcare Quality and Strategy Directorate Pharmacy and Medicines Division Dear Colleague PHARMACEUTICAL SERVICES AMENDMENTS TO DRUG TARIFF IN RESPECT OF SPECIAL PREPARATIONS AND IMPORTED UNLICENSED MEDICINES
More informationSouth Staffordshire and Shropshire Healthcare NHS Foundation Trust
South Staffordshire and Shropshire Healthcare NHS Foundation Trust Document Version Control Document Type and Title: Authorised Document Folder: Policy for Medicines Reconciliation on Admission and on
More informationNon Medical Prescribing Policy Register No: Status: Public
Non Medical Prescribing Policy Policy Register No: 07049 Status: Public Developed in response to: Department of Health Policies, Prescribing Guidance & Legislation Contributes to CQC Outcome: 9 Consulted
More informationDear Colleague. 29 March 2018 GUIDANCE ON THE IMPLEMENTATION OF THE PEER APPROVED CLINICAL SYSTEM (PACS) TIER TWO. Introduction
Directorate for Chief Medical Officer Chief Medical Officer Chief Pharmaceutical Officer Dear Colleague GUIDANCE ON THE IMPLEMENTATION OF THE PEER APPROVED CLINICAL SYSTEM (PACS) TIER TWO Introduction
More informationMedicines Management Guidance
Medicines Management Guidance Status Final Version 1.0 Author Jon Boyd Version date 05/12/2016 Agreed by the following North West London CCGs: Central London West London Hammersmith and Fulham Hounslow
More informationNew v1.0 Date: Cathy Riley - Director of Pharmacy Policy and Procedures Committee Policy and Procedures Committee
Clinical Pharmacy Services: SOP Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date: Key Words:
More informationUnlicensed Medicines Policy Document
Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale
More informationNon medical prescribing policy. Document author Assured by Review cycle. 1. Introduction Purpose or aim Scope...3
Non medical prescribing policy Board library reference Document author Assured by Review cycle P015 Non medical prescribing lead Quality and Standards Committee 3 years This document is version controlled.
More informationAnnouncing the launch of the NICE BNF and NICE BNFC apps in Scotland, Sir Andrew Dillon, NICE Chief Executive, said:
NICE launch free British National Formulary Smartphone Apps for health and social care professionals in partnership with NHS Education for Scotland s Knowledge Network The National Institute for Health
More informationPharmacist (Palliative Care) December 2014 Page 1
Job Profile Job Title: Department: Main Location: Hospice Palliative Care Pharmacist 7 NHS (8SRC) Less than full time(0.8) Full time equivalent around 36,300 Head of Clinical Services 1. Main Purpose of
More informationMs Lyndsey Hands, Graduate Trainee (observer) Mrs Sandra MacDonald (minutes) ACTION
CONFIRMED MINUTES OF THE MEETING OF THE FIFE DRUGS AND THERAPEUTICS COMMITTEE HELD AT 12.30PM ON WEDNESDAY 16 AUGUST 2017 IN MEETING ROOM 2, WARD 6, VICTORIA HOSPITAL, KIRKCALDY. Present: Mrs Evelyn McPhail
More informationabcdefghijklmnopqrstu
Director-General Health and Chief Executive NHS Scotland Dr Kevin Woods abcdefghijklmnopqrstu T: 0131-244 2410 F: 0131-244 2162 E: dghealth@scotland.gsi.gov.uk CEL 4 (2010) Dear Colleague INFORMING, ENGAGING
More informationSupply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over.
Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over. November 2017 Review Nov 2019 Signatures of those developing the Patient Group
More informationSystemic Anti-Cancer Therapy Delivery. June 2017 National External Review
Systemic Anti-Cancer Therapy Delivery June 2017 National External Review Healthcare Improvement Scotland is committed to equality. We have assessed the review process for likely impact on equality protected
More informationGG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Immunisation
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Patients who require an antihistamine
More informationPROCEDURE AND GUIDELINES FOR THE ADMINISTRATION OF MEDICATION IN FOOD OR DRINK TO PEOPLE UNABLE TO GIVE CONSENT TO OR WHO REFUSE TREATMENT MM10
MERSEY CARE NHS FOUNDATION TRUST HOW WE MANAGE MEDICINES Medicines Management Services aim to ensure that (i) Service users receive their medicines at times that they need them and in a safe way. (ii)
More informationNHS HDL (2002) 22 abcdefghijklm
NHS HDL (2002) 22 abcdefghijklm Health Department Dear Colleague SAFE ADMINISTRATION OF INTRATHECAL CYTOTOXIC CHEMOTHERAPY Purpose This circular provides Guidance on the Safe Administration of Intrathecal
More informationStandard Operating Procedure for the administration of Red and Amber Drugs within Integrated Community Care Services
Standard Operating Procedure for the administration of Red and Amber Drugs within Integrated Community Care Services Reference No: Version: 1 Author: Emma Baggaley First Issued On: 1 st March 2018 Latest
More informationCLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD)
CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) DEFINITION A Patient Group Direction (PGD) is a specific written instruction for the supply and administration
More informationIntegrated Care Pathways for Child and Adolescent Mental Health Services. Final Standards June Evidence
Integrated Care Pathways for Child and Adolescent Mental Health Services Final Standards June 2011 Evidence Healthcare Improvement Scotland is committed to equality and diversity. We have assessed these
More informationJob Title Name Signature Date
Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date
More informationPROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS
STANDARD OPERATING PROCEDURE PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS Issue History Issue Version one Purpose of Issue/Description of Change To facilitate patients
More informationThe Medicines Policy. Chapter 6: Standards of Practice. MISCELLANEOUS and DISCHARGE
Chapter 6: Standards of Practice MISCELLANEOUS and DISCHARGE V2.1 Date: October 2015 CHAPTER 6 CONTENTS 6.5. Miscellaneous... 3 6.5.1 Patients Moving Between Healthcare Trusts... 3 6.5.1.1 Transfer of
More informationLiberating the NHS: No decision about me, without me Further consultation on proposals to shared decision-making
Liberating the NHS: No decision about me, without me Further consultation on proposals to shared decision-making Royal Pharmaceutical Society response The Royal Pharmaceutical Society (RPS) is the professional
More informationManaging AHP Practice Placement Cancellations: Guidance
Managing AHP Practice Placement Cancellations: Guidance NHS Education for Scotland AHP Practice Education Programme 2 nd Edition July 2015 Review date: July 2017 AHP Practice Education Programme 1 Content
More informationCroydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement
Shared Care Guideline: Prescribing Agreement Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no: Fax no: NHS.net e-mail: Consultant
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationSupply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2 Date protocol prepared: October 2017 Date protocol due for review: October 2019 Expiry date: October
More informationMedicines Management Strategy
Medicines Management Strategy 2012 2014 Directorate responsible for the strategy: Medical and Governance Directorate Staff group to whom it applies: All clinical staff and Trust managers Issue date: 30/6/12
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) CO-CODAMOL 30/500 TABLETS FOR MINOR INJURIES UNITS Trust Ref No 1956-35206 Local Ref (optional) Main points the document treatment of moderate pain
More informationJOB DESCRIPTION LEAD PRACTICE BASED PHARMACIST. Designated GP Practice in Federation area
JOB DESCRIPTION JOB TITLE: LOCATION: ACCOUNTABLE TO: RESPONSIBLE TO: PROFESSIONALLY RESPONSIBLE TO: LEAD PRACTICE BASED PHARMACIST Designated GP Practice in Federation area Federation Chair Practice Prescribing
More informationAll areas of the Trust All Trust staff All Patients Deputy Chief Nurse & Chief Pharmacist Final
Trust Policy and Procedure Document Ref. No: PP(15)233 Non-Medical Prescribing Policy For use in: For use by: For use for: Document owner: Status: All areas of the Trust All Trust staff All Patients Deputy
More informationCLINICAL AND CARE GOVERNANCE STRATEGY
CLINICAL AND CARE GOVERNANCE STRATEGY Clinical and Care Governance is the corporate responsibility for the quality of care Date: April 2016 2020 Next Formal Review: April 2020 Draft version: April 2016
More informationAuthorisation to Administer Medicines
Authorisation to Administer Medicines Health Guidance Publication date: March 2016 This information sheet is produced for the guidance of Care Inspectorate staff only. The contents should not be regarded
More informationADMINISTRATION OF MEDICATION POLICY G&F ALTERNATIVE PROVISION SCHOOL
Gloucester & Forest Alternative Provision School ADMINISTRATION OF MEDICATION POLICY G&F ALTERNATIVE PROVISION SCHOOL Date:September 2013 PURPOSE The guidance in this policy is to ensure that pupils with
More informationDispensing Medications Practice Standard
October 2013 Updated December 8, 2016 s set out baseline requirements for specific aspects of Registered Psychiatric Nurses practice. They interact with other requirements such as the Code of Ethics, the
More informationSwitch protocol: Brands to generic equivalent
Switch protocol: Brands to generic equivalent Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for
More informationSupply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 1
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 Date protocol prepared: December 2015 Date protocol due for review: December 2017 This patient group direction
More informationIssue: June 2009 PROFESSIONAL STANDARDS AND GUIDANCE FOR PHARMACIST PRESCRIBERS
Issue: June 2009 PROFESSIONAL STANDARDS AND GUIDANCE FOR PHARMACIST PRESCRIBERS PROFESSIONAL STANDARDS AND GUIDANCE FOR PHARMACIST PRESCRIBERS CONTENTS About this document 1 Background 1.1 Types of pharmacist
More informationNHS ISLE OF WIGHT CLINICAL COMMISSIONING GROUP
NHS ISLE OF WIGHT CLINICAL COMMISSIONING GROUP High Cost Drug Policy 1 P age AUTHOR/ APPROVAL DETAILS Document Author Written By: Authorised Signature Authorised By: Helen Shields Tracy Savage and Beth
More informationGuidance on the prescribing of medication initiated or recommended either after a private episode of care or a referral to a tertiary NHS centre
Guidance on the prescribing of medication initiated or recommended either after a private episode of care or a referral to a tertiary NHS centre GUIDELINE VERSION 2 RATIFYING COMMITTEE Drugs and Therapeutics
More informationProvide Safe and Effective Medicines Management in Primary Care
Primary Drivers Secondary Drivers Aim Safe and reliable prescribing, monitoring and administration of high risk medications that require systematic monitoring Implement systems for reliable prescribing
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationThe Scottish Government
The Scottish Government Chief Nursing Officer Directorate Fiona McQueen, Chief Nursing Officer Dear Colleague Physiotherapist, Podiatrist or Independent Prescribing Services Summary Chiropodist The Scottish
More informationPatient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire
More informationSection Title. Prescribing competency framework Catherine Picton, Lead author
Prescribing competency framework Catherine Picton, Lead author What is in this presentation Context Uses of the competency framework Scope of the updated prescribing competency framework Introduction to
More informationNon-Medical Prescribing Strategy
Non-Medical Prescribing Strategy 2014-2017 Nursing & Partnerships Directorate Page 1 of 13 Section Contents Page No. 1. STATEMENT OF INTENT 3 2. PURPOSE 3 3. SCOPE 3 4. BACKGROUND 3 5. STRATEGIC GOALS
More informationPromoting Effective Immunisation Practice Guide for Students, Mentors and Their Employers Updated Click Here
Promoting Effective Immunisation Practice Guide for Students, Mentors and Their Employers Updated 2014 Click Here Promoting Effective Immunisation Practice Published Summer 2014 NHS Education for Scotland
More informationNHS England (Wessex) Clinical Senate and Strategic Networks. Accountability and Governance Arrangements
NHS England (Wessex) Clinical Senate and Strategic Networks Accountability and Governance Arrangements Version 6.0 Document Location: This document is only valid on the day it was printed. Location/Path
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Access to Drugs Policy
The Newcastle upon Tyne Hospitals NHS Foundation Trust Access to Drugs Policy Version No.: 3.0 Effective From: 25 January 2016 Expiry Date: 25 January 2019 Date Ratified: 4 November 2015 Ratified By: Medicines
More informationNon-Medical Prescriber Registration Policy
Non-Medical Prescriber Registration Policy REFERENCE NUMBER Non medical prescribing policy VERSION V1 APPROVING COMMITTEE & DATE Clinical Executive Committee 4.8.15 REVIEW DUE DATE August 2018 1 1. Introduction
More informationNHS and Private Interface Prescribing Guide
NHS and Private Interface Prescribing Guide 1 Background 1.1 The following guide has been developed to assist General Practitioners (GPs) in dealing with requests to prescribe by registered patients following
More informationPROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE
PROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE 1.0 ACTION BY AWMSG: The All Wales Medicines Strategy Group (AWMSG) meeting held on 15 th December 2010 considered and approved the recommendations
More informationPromoting Effective Immunisation Practice
4th Edition 2017 Contents Introduction 3 Who is the programme for? 3 Learning Outcomes 4 Notes for employers 4 Updating 5 Notes for students 6 What are the options for learning? 6 Brief overview of the
More informationSELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING
CLINICAL PROTOCOL SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING RATIONALE Medication errors can cause unnecessary
More informationScotia College of Pharmacists Standards of Practice. Practice Directive Prescribing of Drugs by Pharmacists
Scotia College of Pharmacists Standards of Practice Practice Directive Prescribing of Drugs by Pharmacists September 2014 ACKNOWLEDGEMENTS This Practice Directives document has been developed by the Prince
More information2. The main aims of the implementation facilitator role can be captured by the following objectives:
NICE in Northern Ireland Implementation Facilitator Engagement Activities 2013/14 Executive Summary 1. From 1 October 2012, NICE was able to secure funding, after negotiations with the Department of Health,
More informationDocument Details. notification of entry onto webpage
Document Details Title Patient Group Direction (PGD) Administration of sodium chloride 0.9% injection by registered professionals Trust Ref No 1987-38096 Local Ref (optional) Main points the document As
More informationSafer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS
Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Steve Chaplin describes the NPSA s anticoagulant patient safety alert and the measures it recommends for making the
More informationCommunity Nurse Prescribing (V100) Portfolio of Evidence
` School of Health and Human Sciences Community Nurse Prescribing (V100) Portfolio of Evidence Start date: September 2016 Student Name: Student Number:. Practice Mentor:.. Personal Tutor:... Submission
More informationabcdefghijklmnopqrstu
Health Directorates Healthcare Planning and Policy Dear Colleague SAFE ADMINISTRATION OF INTRATHECAL CYTOTOXIC CHEMOTHERAPY Purpose This circular provides revised guidance on the Safe Administration of
More information